Home > Haematology > EHA 2019 > Bench-to-Bedside > Promising news for gene therapy for sickle cell disease

Promising news for gene therapy for sickle cell disease

Presented By
Dr Olivier Hermine, Necker Hospital, France
Conference
EHA 2019
Trial
Phase 1/2, HGB-206
An engineered lentivirus delivers functional copies of a modified form of the β-globin gene (βA-T87Q-globin gene or LentiGlobin) into a sickle cell disease (SCD) patient’s own haematopoietic stem cells. Once patients have the βA-T87Q-globin gene, they can make functional red blood cells, with the goal of reducing sickled red blood cells, haemolysis, and ensuing complications [1]. In patients who were at least 6 months post-treatment with lentiviral LentiGlobin for SCD, the median level of abnormal sickle haemoglobin was reduced to ≤50% of total haemoglobin. At up to 15 months post-treatment with LentiGlobin, no serious vaso-occlusive crisis (VOEs) or acute chest syndrome were reported in this cohort. In the plenary session, Dr Olivier Hermine (Necker Hospital, France) presented the ongoing, phase 1/2 HGB-206 study. Adults and children living with SCD experience unp...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on